StreetInsider.com News Articles

Form 4 Clearmind Medicine Inc. For: Jun 10 Filed by: HRT FINANCIAL LP

Thu, 18 Jun 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260618/26667143.html

Form 4 Clearmind Medicine Inc. For: Jun 10 Filed by: HRT FINANCIAL LP

Thu, 18 Jun 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260618/26667143.html

Form 6-K Clearmind Medicine Inc. For: Jun 18

Thu, 18 Jun 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20260618/26663208.html

Form 6-K Clearmind Medicine Inc. For: Jun 18

Thu, 18 Jun 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20260618/26663208.html

Clearmind Medicine receives U.S. patent for binge behavior compound

Thu, 18 Jun 2026 07:55:08 -0400

Clearmind Medicine Inc. (Nasdaq: CMND) has been granted U.S. Patent No. 12,350,242, titled "Binge Behavior Regulators," by the United States Patent and Trademark Office, according to a company statement.

The patent covers compositions and methods using a pharmaceutically acceptable salt of the company's molecule MEAI (5-methoxy-2-aminoindane) to regulate binge behaviors, including excessive drinking, eating, and gambling.

The grant brings Clearmind's total portfolio to 32 granted patents across 19 patent families. The company's lead candidate is CMND-100, a central nervous system therapeutic.

CEO Dr. Adi Zuloff-Shani said: "We believe that this milestone directly advances our clinical programs for binge-related disorders, such as alcohol use

Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators

Thu, 18 Jun 2026 07:55:00 -0400

Vancouver, Canada, June 18, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogens-derived therapeutics to solve major under-treated health problems, today announced that it has been granted a U.S. Patent, No. 12,350,242, titled “BINGE BEHAVIOR REGULATORS”, by the United States Patent and Trademark Office (USPTO).

The patent, which refers to Clearmind’s molecule MEAI (5-methoxy-2-aminoindane), covers innovative compositions and methods utilizing a pharmaceutically acceptable salt to regulate binge behaviors, including excessive drinking, eating, and gambling.

Dr.

Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators

Thu, 18 Jun 2026 07:55:00 -0400

Dr.

Form 4 Clearmind Medicine Inc. For: Jun 10 Filed by: HRT FINANCIAL LP

Wed, 17 Jun 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260617/26660588.html

Form 4 Clearmind Medicine Inc. For: Jun 10 Filed by: HRT FINANCIAL LP

Wed, 17 Jun 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260617/26660588.html

Form 4 Clearmind Medicine Inc. For: Jun 10 Filed by: HRT FINANCIAL LP

Tue, 16 Jun 2026 09:19:00 -0400

si-local-file:///var/storage/secattach/20260616/26651767.html

Form 4 Clearmind Medicine Inc. For: Jun 10 Filed by: HRT FINANCIAL LP

Tue, 16 Jun 2026 09:19:00 -0400

si-local-file:///var/storage/secattach/20260616/26651767.html

Form 6-K Clearmind Medicine Inc. For: Jun 16

Tue, 16 Jun 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260616/26650487.html

Form 6-K Clearmind Medicine Inc. For: Jun 16

Tue, 16 Jun 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260616/26650487.html

Clearmind Medicine completes Part A dosing in Phase I/II alcohol disorder trial

Tue, 16 Jun 2026 07:32:58 -0400

Clearmind Medicine Inc. (NASDAQ: CMND) announced the completion of dosing for all 24 participants across four cohorts in Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD), according to a press release dated June 16, 2026.

The trial is a multicenter, randomized, double-blind, placebo-controlled study conducted under U.S. Food and Drug Administration oversight. Participating sites include Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.

All healthy participants in Part A received escalating dose levels of CMND-100, the company's proprietary drug candidate.

"The

Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial